Abstract

This paper mainly analyzes the influence of levothyroxin sodium tablets plus selenious yeast tablets on the effectiveness, thyroid function and prognosis of post-surgical individuals with differentiated thyroid carcinoma. This study selected 190 post-surgical differentiated thyroid carcinoma individuals treated between January 2021 and June 2022. 90 individuals were included in the control group who received levothyroxin sodium tablets therapy and 100 individuals in the research group receiving levothyroxin sodium tablets with selenious yeast tablets therapy. The effectiveness, safety symptoms such as headache, palpitations, insomnia, and gastrointestinal discomfort was assessed. Thyroid function such as thyroid-stimulating hormone, serum free triiodothyronine and free thyroxine between the two groups were evaluated. Further, the prognosis which included recurrence and disease-free survival during 1 y follow-up was observed. Then, differentiated thyroid carcinoma-related markers such as anti-thyroid peroxidase antibody, thyroglobulin and anti-thyroglobulin antibody were comparatively analyzed. The evaluation results showed a markedly higher total effective rate and an evidently lower adverse drug reaction rate in the research group compared with the control group. Besides, thyroid-stimulating hormone, anti-thyroid peroxidase antibody, thyroglobulin and anti-thyroglobulin antibody of the research group reduced notably after medication, lower versus the control group, while free triiodothyronine and free thyroxine elevated statistically, higher compared with the control group. Conclusively, the use of levothyroxin sodium tablets along with selenious yeast tablets for post-surgical differentiated thyroid carcinoma can significantly enhance effectiveness, thyroid function and prognosis necessitating clinical popularization.